Bioporto – executive interview

Published on 22 March 2021

BioPorto is a Denmark-based in vitro diagnostics company that uses antibody and assay expertise to transform novel research tools into clinically actionable biomarkers. The company’s portfolio includes The NGAL Test for the prediction of acute kidney injury and an extensive antibody library.

In this video, Peter Eriksen, BioPorto’s chief executive officer, highlights the company’s year-end earnings results and discusses the status of its resubmission timeline to the FDA for pediatric The NGAL Test. He also provides an update on the corporate outlook for 2021 and reviews a new vision for the product portfolio with a focus on expanding BioPorto’s proprietary gRAD technology.

Share this with friends and colleagues